行情

DVAX

DVAX

德纳维制药
NASDAQ

实时行情|Nasdaq Last Sale

3.530
-0.030
-0.84%
盘前: 3.330 -0.2 -5.66% 08:14 04/01 EDT
开盘
3.530
昨收
3.560
最高
3.690
最低
3.370
成交量
114.28万
成交额
--
52周最高
8.19
52周最低
1.800
市值
3.04亿
市盈率(TTM)
-1.6011
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测DVAX价格均价为13.67,最高价位20.00,最低价为9.00。

EPS

DVAX 新闻

更多
  • These 19 companies are working on coronavirus treatments or vaccines heres where things stand
  • MarketWatch · 17小时前
  • Week In Review: Abbisko Raises $70 Million To Develop Cancer Drug Candidates
  • Seeking Alpha - Article · 2天前
  • 三叶草生物与美国Dynavax合作评估新冠候选疫苗与CpG 1018佐剂的...
  • 新浪财经 · 4天前
  • Dynavax's stock rises 10% on expanded CEPI partnership
  • MarketWatch · 5天前

所属板块

生物技术和医学研究
-0.49%
制药与医学研究
-0.25%

热门股票

代码
价格
涨跌幅

DVAX 简况

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
展开

微牛提供Dynavax Technologies Corporation(NASDAQ-DVAX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的DVAX股票新闻,以帮助您做出投资决策。